ArticleJournal of gastrointestinal oncology2026
Patterns of recurrence and outcomes of poor responders to neoadjuvant long-course chemoradiotherapy for rectal cancer.
Article in Journal of gastrointestinal oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant chemoradiotherapy (nCRT) followed by surgery and adjuvant chemotherapy is a standard therapy for locally advanced rectal cancer (LARC). However, a significant proportion of patients exhibit a poor response, and few studies focus on this subgroup's prognosis. The aim of this study was to investigate the prognosis of locally advanced rectal cancer patients with poor response to neoadjuvant chemoradiotherapy. Methods: Between July 2013 and August 2023, we retrospectively collected data from patients with LARC who received long-course nCRT and surgery at our hospital. Patients with tumor regression grade 3 were defined as poor responders, and their recurrence patterns, long-term oncological outcomes were analyzed. Results: A total of 135 patients were included in the analysis, with a median follow-up duration of 45 months. Recurrence occurred in 65 patients, with the following recurrence patterns: locoregional recurrence (n=12), lung metastasis (n=19), liver metastasis (n=8), metastases to other sites (n=3), multiple-site recurrence (n=13) and unknown site (n=10). The 5-year overall survival and 3-year disease-free survival were 56.8% and 53.1%, respectively. Despite poor response to nCRT, adjuvant chemotherapy emerged as an independent protective factor for overall survival [hazard ratio (HR) =0.415, 95% confidence interval (CI): 0.185-0.930, P=0.03]. Conclusions: Poor responders to nCRT in LARC have high risk of recurrence and metastasis, especially lung metastasis. Adjuvant chemotherapy could improve the overall survival in this group.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.